title: Pharmacokinetics of (R)- and (S)-cyclophosphamide and their dechloroethylated metabolites in cancer patients.
abstract: The complete pharmacokinetics (PK) of (R)- and (S)-cyclophosphamide (CP) and their dechloroethylated (DCE) metabolites have not been reported to date. We collected plasma and urine samples from 12 cancer patients and determined concentrations of both enantiomers of CP and DCE-CP using a chiral GC-MS method. All concentrations of (R)-CP, (S)-CP, (R)-DCE-CP, and (S)-DCE-CP were simultaneously modeled using an enantiospecific compartmental PK model. A population PK analysis was performed. Enantiospecific differences between (R)- and (S)-CP were found for the formation clearance of CP to the DCE metabolites (Clf: 0.25 (R) vs. 0.14 (S) L/h). No difference was found between enantiomers for Cl40H, Cld, Cl(m)R, ClT, or T1/2. In contrast to the adolescent and adult group of patients, a child (6 years old) appeared to have a very different PK and metabolic profile (Bayesian control analysis). Proportions of the (R,S)-CP doses transformed to the (R)-DCE- and (S)-DCE-CP were much higher (R: 25 vs. 1.9%, and S: 38 vs. 3.6%), while formation of active metabolites was much lower (R: 42 vs. 74%, and S: 48 vs. 77%). CP appears to be enantioselectively metabolized to the DCE metabolites. This PK model can evaluate the proportion of a CP dose that is transformed to toxic or active metabolites. It may therefore be used to optimize CP treatment, to identify important drug interactions and/or patients with an abnormal metabolic profile.
authors.affiliation: Faculty of Pharmacy, University of Montreal, Canada.
authors.forename: M L
authors.initials: ML
authors.lastname: Williams
authors.forename: I W
authors.initials: IW
authors.lastname: Wainer
authors.forename: C P
authors.initials: CP
authors.lastname: Granvil
authors.forename: B
authors.initials: B
authors.lastname: Gehrcke
authors.forename: M L
authors.initials: ML
authors.lastname: Bernstein
authors.forename: M P
authors.initials: MP
authors.lastname: Ducharme
mesh_terms: D000293:Adolescent; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001711:Biotransformation; D003520:Cyclophosphamide / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods; D006801:Humans; D008657:Metabolic Clearance Rate; D008954:Models, Biological; D009369:Neoplasms / Q000097:blood* / Q000188:drug therapy; D013237:Stereoisomerism
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide